Astrazeneca (AZN) Gross Profit (2009 - 2026)

Astrazeneca has reported Gross Profit for 18 years, with the latest figure at $12.9 billion in Q2 2026.

• On a quarterly basis, Gross Profit rose 7.32% year-over-year to $12.9 billion in Q2 2026; TTM through Jun 2026 was $50.2 billion, a 9.28% increase from a year earlier, with the FY2025 full-year figure at $48.1 billion, up 9.67% from the prior year.
• Gross Profit was $12.9 billion for Q2 2026 at Astrazeneca, up from $12.6 billion in the prior quarter.
• The five-year high for Gross Profit was $27.8 billion in Q4 2023, with the low at $7.8 billion in Q2 2022.
• Average Gross Profit over 5 years is $11.4 billion, with a median of $10.6 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Gross Profit jumped 234.98% in 2023, then sank 56.28% in 2024.
• Over 5 years, Gross Profit stood at $8.3 billion in 2022, then surged by 234.98% to $27.8 billion in 2023, then tumbled by 56.28% to $12.2 billion in 2024, then gained by 1.8% to $12.4 billion in 2025, then rose by 3.84% to $12.9 billion in 2026.
• The last three Gross Profit figures came in at $12.9 billion (Q2 2026), $12.6 billion (Q1 2026), and $12.4 billion (Q4 2025), per Business Quant data.